摘要
伊马替尼、第二代和第三代ABL癌基因蛋白质络氨酸激酶抑制剂(TKI)(也即达沙替尼、尼龙替尼、伯舒替尼和泊那替尼)的使用使得CML(慢性粒细胞白血病)在部分案例中成为临床上一个可控制和治愈的疾病。TKI治疗CML急变也变成了一个罕见的事件,然而,疾病仍然在部分TKI治疗无效或者对多种TKIs产生耐药的患者发展。过去的几年,人们开始了解到BSRAB1基因不是单独推动疾病的发生、维护和发展,事实上似乎骨髓(BM)微环境产生的信号和细胞自治BCRANL1依赖激酶的基因和表观遗传的改变都有助于一下几点:1.静态白血病干细胞的持久性(LSC)储层2.先天或获得性TKIs耐药性3.发展成致病的急性危急阶段。在此本文综述了复杂网络中的异常情况,但是微调、生存、增殖和自我更新的信号是由白血病祖细胞、间质细胞、免疫细胞、代谢微环境(如缺氧)产生,为提高LSC的维护和急变转换。
关键词: 干细胞、微环境、慢性髓细胞样白血病、造血干细胞
图形摘要
Current Drug Targets
Title:Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Volume: 18 Issue: 4
关键词: 干细胞、微环境、慢性髓细胞样白血病、造血干细胞
摘要: The use of imatinib, second and third generation ABL tyrosine kinase inhibitors (TKI) (i.e. dasatinib, nilotinib, bosutinib and ponatinib) made CML a clinically manageable and, in a small percentage of cases, a cured disease. TKI therapy also turned CML blastic transformation into a rare event; however, disease progression still occurs in those patients who are refractory, not compliant with TKI therapy or develop resistance to multiple TKIs. In the past few years, it became clear that the BCRABL1 oncogene does not operate alone to drive disease emergence, maintenance and progression. Indeed, it seems that bone marrow (BM) microenvironment-generated signals and cell autonomous BCRABL1 kinase-independent genetic and epigenetic alterations all contribute to: i. persistence of a quiescent leukemic stem cell (LSC) reservoir, ii. innate or acquired resistance to TKIs, and iii. progression into the fatal blast crisis stage. Herein, we review the intricate leukemic network in which aberrant, but finely tuned, survival, mitogenic and self-renewal signals are generated by leukemic progenitors, stromal cells, immune cells and metabolic microenvironmental conditions (e.g. hypoxia) to promote LSC maintenance and blastic transformation.
Export Options
About this article
Cite this article as:
Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay, Current Drug Targets 2017; 18 (4) . https://dx.doi.org/10.2174/1389450117666160615074120
DOI https://dx.doi.org/10.2174/1389450117666160615074120 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Impact of Hypertension as a Road to Heart Failure with Preserved Ejection Fraction: Diagnostic Value of Two-Dimensional Speckle Tracking Echocardiography for the Early Impairment of Left Atrial-Left Ventricular-Arterial Coupling
Current Hypertension Reviews Is Combined Angiotensin-converting Enzyme Inhibition and Angiotensin Receptor Blockade Associated with Increased Risk of Cardiovascular Death in Hemodialysis Patients?
Current Hypertension Reviews Human Galectin-3 Selective and High Affinity Inhibitors. Present State and Future Perspectives
Current Medicinal Chemistry Alteration of the Beta-Adrenergic Signaling Pathway in Human Heart Failure
Current Pharmaceutical Biotechnology Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design The Relationship Between Diabetes Mellitus, Geriatric Syndromes, Physical Function, and Gait: A Review of the Literature
Current Diabetes Reviews Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets The Chromogranin A-Derived Vasostatins: New Players in the Endocrine Heart
Current Medicinal Chemistry SAR, Cardiac Myocytes Protection Activity and 3D-QSAR Studies of Salubrinal and its Potent Derivatives
Current Medicinal Chemistry Pharmacogenomics of Cardiovascular Complications in Diabetes and Obesity
Recent Patents on Biotechnology Atherosclerotic Plaque Stabilization - Potential Role for Immunomodulatory Therapy
Vascular Disease Prevention (Discontinued) Recent Applications of Benzimidazole as a Privileged Scaffold in Drug Discovery
Mini-Reviews in Medicinal Chemistry Halting Arterial Aging in Patients with Cardiovascular Disease: Hypolipidemic and Antihypertensive Therapy
Current Pharmaceutical Design Effects of Myricitrin and Relevant Molecular Mechanisms
Current Stem Cell Research & Therapy Alcohol Induced Hepato Cardiotoxicity and Oxidative Damage in Rats: The Protective Effect of n-butanol Extract of Green Tea (Camellia sinensis (L.) Kuntze)
Cardiovascular & Hematological Disorders-Drug Targets Pulmonary Arterial Hypertension in Connective Tissue Diseases
Current Respiratory Medicine Reviews Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design Interactions of Cnidarian Toxins with the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) The p35 Family of Apoptosis Inhibitors
Current Genomics